To print: Select File and then Print from your browser's menu

Title: FDA MedWatch - Cefazolin for Injection Recalled Due to Microbial Contamination of Active Ingredient

"FDA MedWatch - Cefazolin for Injection Recalled Due to Microbial Contamination of Active Ingredient"

BETHESDA, M.D. -- March 2, 2006 -- Hanford Pharmaceuticals and the United States Food and Drug Administration (FDA) notified healthcare professionals about the recall of four lots (379,975 vials) of Cefazolin for Injection, USP, 1 g/10 mL vials, an antibiotic used in a hospital environment to treat skin and skin structure, respiratory and other infections. The product was distributed by Sandoz, Inc. of Broomfield, Colorado, and Watson Pharmaceuticals, Inc. of Corona, California. Certain lots of the active ingredient used to manufacture the product have been shown to contain microbial contamination (Bacillus pumilus, Staphylococcus hominis, Propionibacterium acnes, or Micrococcus luteus) which may pose a serious or life-threatening risk for some patients. Hospitals, clinics, and users should stop using the affected lots immediately. SOURCE: The FDA Safety Information and Adverse Event Reporting Program

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.